SEARCH

SEARCH BY CITATION

  • 1
    Karpeh MS, Kelsen DP, Tepper JE. Cancer of the stomach. In: DevitaVTJr, HellmanS, RosenbergSA, editors. Cancer: principles' practice of oncology. 6th ed. Philadelphia : Lippincott Williams' Wilkins; 2001. p. 1092121.
  • 2
    Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, Sugimachi K, Saku M. Clinicopathologic study of patients with Borrmann type IV gastric carcinoma. J Surg Oncol 1995; 58: 1127.
  • 3
    Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 27788.
  • 4
    Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N, Itoh K. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001; 61: 203846.
  • 5
    Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 405663.
  • 6
    Niiya F, Nishizaka S, Matsunaga K, Koufuji K, Mori M, Katai H, Yamana H, Itoh K. Expression of SART3 tumor-rejection antigen in gastric cancers. Jpn J Cancer Res 2000; 91: 33742.
  • 7
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 32127.
  • 8
    Gohara R, Imai N, Rikimaru T, Yamada A, Hida N, Ichiki M, Kawamoto M, Matsunaga K, Ashihara J, Yano S, Tamura M, Ohkouchi S, Yamana H, Oizumi K, Itoh K. Phase 1 clinical study of cyclophilin B peptide vaccine for lung cancer patients. J Immunother 2002; 25: 43944.
  • 9
    Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001; 7: 395062.
  • 10
    Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 54856.
  • 11
    Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Tamura M, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in the periphery. J Immunother 2003; 26: 35766.
  • 12
    Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate in press.
  • 13
    Maeda Y, Hida N, Niiya F, Katagiri K, Harada M, Yamana H, Kamura T, Takahashi M, Sato Y, Todo S, Itoh K. Detection of peptide-specific CTL-pre-cursors in peripheral blood lymphocytes of cancer patients. Br J Cancer 2002; 87: 796804.
  • 14
    Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002; 51: 21928.
  • 15
    Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168: 141941.
  • 16
    Kawamoto N, Yamada A, Ohkouchi S, Maeda T, Tanaka S, Hashimoto T, Saijo Y, Saijo S, Nukiwa T, Shichijo S, Aizawa H, Itoh K. IgG reactive to CTL-directed epitopes of self-antigens is entirely lacking or unbalanced in atopic dermatitis patients. Tissue Antigens 2003; 61: 35261.
  • 17
    Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, Tomura M, Ono S, Tsujimura T, Fujiwara H, Hamaoka T. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res 2001; 61: 3399405.